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Abstract: Although HOX genes are best known for acting in the regulation of important events during embryogenesis, 
including proliferation, differentiation and migration, alterations in their expression patterns have been frequently 
described in cancers. In previous studies we analyzed the expression profile of the members of the HOX family of 
homeobox genes in oral samples of normal mucosa and squamous cell carcinoma (OSCC) and identified differently 
expressed genes such as HOXA10. The present study aimed to validate the increased expression of HOXA10 in 
OSCCs, and to investigate the effects arising from its knockdown in OSCC cells. The levels of HOXA10 mRNA were 
determined in human OSCC samples and cell lines by quantitative PCR, and HOXA10-mediated effects on prolifera-
tion, apoptosis, adhesion, epithelial-mesenchymal transition (EMT), migration and invasion were studied in HSC-3 
tongue carcinoma cells by using retrovirus-mediated RNA interference. Higher expression of HOXA10 mRNA was 
observed in OSCC cell lines and in tumor tissues compared to normal controls. HOXA10 knockdown significantly re-
duced the proliferation of the tumor cells which was accompanied by increased levels of p21. HOXA10 silencing also 
significantly induced the expression of EMT markers and enhanced the adhesion, migration and invasion of HSC-3 
cells. No effects on cell death were observed after HOXA10 knockdown. The results of the current study confirm 
the overexpression of HOXA10 in OSCCs, and further demonstrate that its expression is functionally associated with 
several important biological processes related to oral tumorigenesis, such as proliferation, migration and invasion.
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Introduction
HOX genes are members of the superfamily of 
homeobox genes that encode transcription fac-
tors involved in the control of cell growth and 
identity [1, 2], as well as in cell-cell and cell-
extracellular matrix interactions [3]. Deregu- 
lated expression of HOX genes has been 
described in leukemia, breast, cervical, ovarian 
and prostate cancers, among others [4-8]. 
Aberrant expression of HOX genes was also 
observed in oral squamous cell carcinomas 
(OSCCs) [9-19]. However, few studies have att- 
empted to elucidate the involvement of HOX 
genes in oral tumorigenesis. In previous stud-
ies, we showed that most of the genes in the 
HOXB network are inactive in oral normal tis-
sues, but the gain of HOXB7 expression in 
OSCCs leads to increased tumor cell prolifera-
tion [10, 14]. Increased expression of HOXA1 in 
OSCCs induced cell proliferation and was asso-
ciated with poor prognosis [15].
After the first evidence that the aberrant expres-
sion of HOXA10 is associated with leukemia 
[20], the role of HOXA10 in tumor development 
and progression has been investigated [21-26]. 
However, the results are somehow controver-
sial suggesting a dual role of HOXA10 in can-
cers. Both upregulation and downregulation of 
HOXA10 expression have been associated with 
cellular processes related to cancer, including 
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proliferation, apoptosis, epithelial-mesenchy-
mal transition (EMT) and treatment resistance 
[3, 27-29]. In OSCCs, the expression of HOXA10 
was significantly higher in cancer cell lines and 
in primary tumors compared to controls, and 
the protein encoded by HOXA10 was correlated 
with disease stage, indicating its potential use 
as a prognostic marker [11]. In the present 
study, we further investigated the expression of 
HOXA10 in cell lines and in samples from nor-
mal oral mucosa and OSCC. We also evaluated 
the effects of HOXA10 knockdown on prolifera-
tion, apoptosis, adhesion, expression of EMT 
markers, migration and invasion of OSCC cells.
Materials and methods
Samples
Tissue samples were collected after approval 
of the Human Research Ethics Committee of 
the School of Dentistry, University of Campinas. 
Fresh samples of normal oral mucosa (n=12) 
and OSCC (n=12) were used to investigate the 
expression of HOXA10 using quantitative PCR 
(qPCR). The samples were divided into two 
parts: one was fixed in formalin and embedded 
in paraffin for hematoxylin and eosin staining, 
while the other was snap frozen in liquid nitro-
gen. The initial diagnosis was based on clinical 
findings and confirmed by histopathological 
analysis of the specimens.
Cell cultures and generation of HOXA10 knock-
down cells
Normal human gingival keratinocyte cell line 
(HGK) was cultured in serum-free, low calcium 
medium (Gibco’s Keratinocyte-SFM; Invitrogen, 
USA) containing specific supplements and anti-
biotics [30]. The human OSCC cell lines SCC-4, 
SCC-9, SCC-15 and SCC-25 were obtained from 
American Type Culture Collection (ATCC, Ma- 
nassas, VA, USA), and cultured as recommend-
ed in a 1:1 mixture of Dulbecco’s modified 
Eagle’s medium and Ham’s F12 medium 
(DMEM/F12; Invitrogen, USA) supplemented 
with 10% fetal bovine serum (FBS), 400 ng/ml 
hydrocortisone (Sigma-Aldrich, USA) and antibi-
otics. HSC-3, a human tongue squamous cell 
carcinoma cell line (JCRB 0623; Osaka National 
Institute of Health Sciences, Japan), was cul-
tured in DMEM/F-12 medium (Invitrogen, USA) 
supplemented with 10% FBS, 50 µg/ml ascor-
bic acid (Sigma-Aldrich, USA), 400 ng/ml hydro-
cortisone (Sigma-Aldrich, USA) and antibiotics. 
All cells were growth at 37°C in a humidified 
atmosphere of 5% CO2.
Transduction of HSC-3 cells with shRNA 
sequences was performed using the human 
Phoenix packaging cells (293T cells) according 
to the manufacturer’s instructions (OriGene 
Technologies, USA). After transduction, cells 
were selected in the presence of 1 μg/ml of 
puromycin (Invitrogen, USA) for 2 weeks.
qPCR
Total RNA from cell lines and fresh samples 
was isolated with TRIzol reagent according to 
the manufacturer’s protocol (Invitrogen, USA). 
Following DNase I treatment in order to elimi-
nate genomic DNA contamination, 2 μg of total 
RNA per sample were used to generate cDNA 
using Oligo-dT primers (Invitrogen, USA) and a 
superscript enzyme (Superscript II RT enzyme, 
Invitrogen, USA). The resulting cDNAs were sub-
jected to qPCR using SYBR® Green PCR master 
mix (Applied Biosystems, USA) in the Step- 
OnePlus Real Time PCR (Applied Biosystems, 
USA). Gene expressions were determined by 
the standard curve method or deltadeltaCT 
with normalization to the housekeeping gene 
PPIA (cyclophilin A). Primer sequences are 
described in Table 1.
Western blot
Cells were washed with cold PBS and lysed in a 
protein-lysis buffer containing 20 mM Tris pH 
8.0, 137 mM NaCl, 10% glycerol, 2 mM EDTA 
and protease inhibitors. After centrifugation, 
protein concentrations were measured using a 
protein assay according to the manufacturer’s 
instructions (Bio-Rad Protein Assay, Bio-Rad, 
USA). Eighty μg of total protein per sample were 
Table 1. Primer sequences used in the qPCR
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’)
HOXA10 GGTACGGACAGACAAGTGAAAATCTT GGAAGTGAAAAAACCGCGTCGCCTGG
PPIA GCTTTGGGTCCAGGAATGG GTTGTCCACAGTCAGCAATGGT
E-Cadherin ACAGCCCCGCCTTATGATT TCGGAACCGCTTCCTTCA
N-Cadherin TGGGAATCCGACGAATGG GCAGATCGGACCGGATACTG
HOXA10 expression in oral cancer
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resolved in a 10% sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) 
under reducing conditions, and transferred to 
nitrocellulose membranes. The membranes we- 
re blocked with 10% non-fat dry milk in PBS 
containing 0.1% Tween-20, rinsed in the same 
buffer, and incubated for 2 h with anti-HOXA10 
(clone A20, Santa Cruz, USA), anti-p21 (clone 
C-19, Santa Cruz, USA) or anti-β-actin antibod-
ies (Sigma-Aldrich, USA). After washing, the me- 
mbranes were developed using an enhanced 
chemiluminescent western blot kit (GE Health- 
care, Austria).
Bromodeoxyuridine-labeling (BrdU) index
Cells were plated in 96-well chamber slides at a 
density of 3,000 cells per well in complete 
media. After 24 h, cells were washed with PBS 
and cultured in serum-free media for 48 h for 
synchronism. Following serum starvation, cul-
ture media containing 10% of FBS was added 
to the cells. BrdU, a thymidine analog, was 
added to the cultures in 1:10 dilution and kept 
for 2 h at 37°C in 5% CO2. After incubation, the 
media was removed and manufacturer’s proto-
col (Cell proliferation ELISA BrdU colorimetric 
assay kit, Roche Applied Science, Germany) 
was followed. Absorbance was measured at 
370 nm with correction at 492 nm.
Apoptosis analysis
The apoptosis index was determined by annex-
in V-FITC labeling. Succinctly, cells were har-
vested, washed with PBS and resuspended in 
the binding buffer (10 mM HEPES pH 7.4, 150 
mM NaCl, 5 mM KCl, 1 mM MgCl2 and 1.8 mM 
CaCl2) containing annexin V-FITC (BD Biosci- 
ences, USA) and propidium iodide (PI, Sigma-
Aldrich, USA). Samples were incubated for 20 
min at room temperature, and shielded from 
light. Apoptosis was analyzed on a FACScalibur 
flow cytometer equipped with an argon laser 
(BD Biosciences, USA) and quantified as the 
number of annexin V-FITC positive and PI nega-
tive cells divided by the total number of cells. A 
minimum of 10,000 events was analyzed in 
each sample.
Cell adhesion assay
A 96-well culture plate was coated with 2 μg of 
type I collagen or fibronectin (BD Biosciences, 
USA) in 100 μl of PBS for 16 h at 4°C. The wells 
were washed 3 times with 200 μl of PBS and 
then coated with the same volume of 3% of 
BSA in PBS for 2 h at 37°C. Control wells were 
coated only with 3% BSA solution. Cells were 
harvested and then resuspended in DMEM 
supplemented with 10% FBS and 3% BSA at a 
final concentration of 3,000 cells in 100 μl. The 
wells were washed and then 100 μl of the cell 
suspension was added to each well. The plate 
was then kept for 1 h in 37°C at 5% CO2. Loose 
cells were washed away and adhered cells were 
fixed in 10% formalin for 15 min and stained 
with a solution of 1% toluidin blue and 1% bo- 
rax. Absorbance was measured at 650 nm.
Analysis of the EMT markers
The expression of the epithelial marker E- 
cadherin and of mesenchymal marker N-ca- 
dherin was carried out using western blot and 
qPCR analysis as described above. The mono-
clonal antibodies anti-E-cadherin and anti-N-
cadherin were purchased from BD Biosciences 
(USA) and used at concentrations of 1:2000 
and 1:2500, respectively.
Migration and invasion assays
Transwell migration and invasion assays were 
performed in 6.5 mm inserts with 8 μm pore 
size (Corning, USA). For invasion assay, mem-
branes were coated with 50 µl of growth factor-
reduced matrigel (BD Biosciences, USA). Serum 
starved cells (80,000 cells/well) were plated 
into the upper chamber in 200 μl of serum-free 
DMEM. As chemoattractant, 500 μl of com-
plete medium was used in the lower chamber. 
Experiment times varied between 24 h for 
migration assays and 72 h for invasion assays. 
Assessment of migration or invasion was per-
formed by gently removing cells in the interior 
part of the insert with a cotton swab. Cells in 
the bottom of the membrane were fixed in 10% 
formalin for 15 min and stained with a solution 
of 1% toluidine blue and 1% borax. The excess 
dye was washed and the plate was incubated 
with a solution of 1% SDS for 5 min. Absorbance 
was measured at 650 nm.
Statistical analysis
All assays were performed at least three times 
in triplicates or quadruplicates. Data represent 
the percentage of the mean ± standard devia-
tion of the corresponding controls. Kruskal-
HOXA10 expression in oral cancer
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Wallis test and Mann-Whitney U test were app- 
lied in our comparisons, and P≤0.05 was con- 
sidered as indicating of statistical significance.
Results
To confirm the differential expression of 
HOXA10 in oral cancers, we first evaluated the 
expression levels of HOXA10 in different cell 
lines and in fresh tissues. The levels of HOXA10 
mRNA were significantly higher in the OSCC cell 
lines SCC-4 (P<0.0001), SCC-15 (P<0.0001), 
SCC-25 (P=0.005) and HSC-3 (P=0.001) com-
pared with the spontaneously immortalized, 
but not transformed epithelial cell line HGK 
(Figure 1A). Although higher, the expression 
levels of SCC-9 did not reach a statistically sig-
nificant difference when compared to HGK 
(P=0.20). A significantly higher content of 
HOXA10 mRNA was observed in the fresh 
Figure 1. HOXA10 is overexpressed in OSCCs and OSCC-derived cell lines. Total RNA from cell lines and fresh sam-
ples were converted in cDNA and subjected to qPCR. A. HOXA10 mRNA levels were significantly higher in OSCC cell 
lines compared to normal human oral keratinocyte cells (HGK), with exception of SCC-9. B. The amount of HOXA10 
mRNA was significantly higher in OSCCs than in adjacent normal oral mucosa. *P=0.003.
Figure 2. RNAi-mediated silencing of HOXA10 expression in HSC-3 cells. Representative qPCR (A) and western blot 
(B) analysis of HOXA10 in HSC-3-Control and HSC-3-shHOXA10, which confirmed the marked reduction of HOXA10 
levels in HSC-3-shHOXA10 cells.
HOXA10 expression in oral cancer
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tumors in comparison to normal control tissues 
(P=0.003, Figure 1B).
In order to comprehend the biological role of 
HOXA10 in the events that control tumorigene-
sis, the levels of HOXA10 were specifically sil- 
enced using interference RNA in the HSC-3 cell 
line, the most invasive OSCC cell line. After 
stable retroviral transduction and selection of 
puromycin-resistant cells, both HOXA10 mRNA 
and protein levels were quantified by qPCR and 
western blot. Although the HOXA10 mRNA lev-
els were only reduced by ~50% in comparison 
with the control cells (HSC-3-Control), the 
HOX10A protein levels were markedly reduced 
in cells transduced with specific shRNA against 
HOXA10 mRNA (HSC-3-shHOXA10, Figure 2).
The effects of HOXA10 on proliferation and cell 
death (apoptosis) were investigated by using 
BrdU-labeling index and Annexin-V assays. As 
depicted in Figure 3A, no significant differenc-
es in apoptosis were observed between the 
HSC-3-shHOXA10 and control cells, but the 
proliferation rate of the HSC-3-shHOXA10 cells 
was significantly reduced compared with the 
HSC-3-Control cells (P<0.0001, Figure 3B). As 
a previous study has shown that HOXA10 con-
trols p21 expression leading to decrease cell 
cycle progression [27], we sought to evaluate 
p21 levels in HSC-3-shHOXA10 cells using we- 
stern blot analysis. Consistently, increased p21 
expression was observed in HSC-3-shHOXA10 
cells compared to controls (Figure 3C).
Next, the effects of HOXA10 on cell invasion 
and migration were assessed in transwell 
chambers. Even in the presence of a large stan-
dard deviation, HSC-3-shHOXA10 cells exhibit-
ed significantly augmented migration (P< 
0.0001) and invasion (P=0.002) capacity when 
compared with HSC-3-Control cells (Figure 4). 
Furthermore, down-regulation of HOXA10 was 
Figure 3. Inhibition of HOXA10 alters proliferation 
but not apoptosis in HSC-3 cells. A. No significant 
effects on apoptosis were observed in HSC-3 
cells after knock down of HOXA10 as evaluated by 
annexin V stain. B. BrdU incorporation assay re-
vealed a significantly reduction in proliferation of 
HSC-3-shHOXA10 in comparison to control cells. 
C. Reduction on cell proliferation after blockage 
of HOXA10 was accompanied by higher levels of 
p21. *P<0.0001.
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followed by a significant increase in cell adhe-
sion on surfaces coated with fibronectin (P= 
0.049) or type I collagen (P=0.049). Although 
the adhesion of HSC-3-shHOXA10 cells was 
higher than HSC-3-Control in the uncoated sur-
faces, the difference was not significant (P= 
0.13, Figure 5). To determine whether HOX-A10 
levels regulate EMT, we examined the expres-
sion levels of the epithelial marker E-cadherin 
and of the mesenchymal marker N-cadherin in 
the HOXA10 silencing cells. As revealed in 
Figure 6A, HSC-3-shHOXA10 had high mRNA 
levels of N-cadherin and reduced expression of 
E-cadherin. Using protein immunoblotting, we 
confirmed that HSC-3-shHOXA10 cells con-
tained increased protein levels of N-cadherin 
and slight decreased levels of E-cadherin 
(Figure 6B).
Discussion
HOX genes encode transcription factors that 
control important cellular events such as cell 
proliferation, differentiation and death during 
the early phases of development [31]. Their 
contribution to tumorigenesis is widely accept-
ed, although the exact mechanisms through 
which they exert their functions are not yet 
clear [32, 33]. The relationship between HO- 
XA10 and oral tumorigenesis was initially 
described by Hassan et al. [9] in a study that 
verified the expression pattern of all HOX genes 
in normal, dysplastic and tumor tissues. Since 
then, Yamatoji and colleagues [11] detected an 
aberrant expression of HOXA10 in OSCCs and 
OSCC-derived cell lines. Similarly, our group 
demonstrated that HOXA10 expression was 
significantly higher in OSCC samples compared 
to both healthy oral mucosa and histologically 
normal mucosa adjacent to OSCC [15]. This 
motivated this in depth analysis on the role of 
HOXA10 in oral carcinogenesis. Therefore, we 
chose to validate our data by testing different 
cells lines and fresh samples from OSCC and 
adjacent normal oral mucosa, which confirmed 
our previous findings that HOXA10 mRNA levels 
are significantly higher in tumors when com-
pared to normal oral mucosa. The most impor-
tant finding of the current study was that knock-
down of HOXA10 significantly reduced the 
proliferation of OSCC cells, while concomitantly 
induced cell adhesion, expression of EMT mark-
ers and migration and invasion of the cells.
Although several studies have verified the role 
of HOXA10 as a potential prognostic marker, 
the results showed discrepancies [1, 34-36]. 
Multiple evidences showed that HOXA10 is 
involved in the proliferation of hematopoietic 
stem cells and progenitor cells, leading to can-
cer development through the activation of sev-
eral target genes, including TGF-β2, dual-speci-
ficity protein phosphatase 4 and integrin-β3 [1, 
34, 36]. Up-regulation of HOX genes is associ-
ated with a tumor stem-like cell phenotype of 
glioblastoma, and high HOXA10 protein expres-
Figure 4. Migration and invasion of HSC-3 were induced after HOXA10 knock down. (A) Migration and (B) invasion 
were evaluated by transwell system. Both migration and invasion were significantly increased by HOXA10-specific 
shRNA. *P<0.0001, **P=0.002.
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sion has been implicated with resistance to 
chemotherapy [35]. Furthermore, expression of 
HOXA10 was negatively correlated with the 
depth of invasion in gastric carcinomas, and 
the prognosis of patients with positive HOXA10 
expression was significantly better than in 
cases where HOXA10 was absent [37]. In addi-
tion, overexpression of HOXA10 was associat-
ed with gastric tumors showing poor-prognostic 
features [38]. On the other hand, loss of HO- 
XA10 expression was associated with poor 
tumor differentiation in endometrial and ovari-
an tumors, indicating that a lower expression of 
HOXA10 worsen patient’s prognosis [3, 39]. HO- 
XA10 methylation has been described in sev-
eral types of cancer and was correlated with 
different histologic grading, as well as prognos-
tic and clinicopathological characteristics [40-
43]. In breast and ovarian cancer, miR-135a 
directly regulated HOXA10 expression, which 
promoted cell migration and invasion [44, 45]. 
Taken together, these findings suggest that the 
role of HOXA10 is variable and tumor lineage 
dependent.
Regardless of the mechanism by which HOXA10 
expression is upregulated in OSCCs, we showed 
in this study that HOXA10 is an important regu-
lator of proliferation, adhesion, migration and 
invasion of OSCC cells. HOXA10 downregula-
tion led to an increase in p21 expression and a 
reduction of cell proliferation rate. This result is 
in agreement with previous findings of transac-
tivation of p21 by direct binding of HOXA10 
onto the p21 promoter in breast cancer cells 
[27]. A lower proliferative capacity was also 
noticed in mice after bone marrow transplant 
with HOXA10 knockdown cells when compared 
to control animals [46]. As expected, in vitro 
analysis of such cells indicated a shift on cell 
cycle with reduced number of cells on S-phase 
[46]. Forced expression of HOXA10 significantly 
Figure 5. Effects of HOXA10 downregulation 
on adhesion of HSC-3 cells. Both HSC-3-Con-
trol and HSC-3-shHOXA10 cells were harvest-
ed and allowed to adhere for 1 h to wells of 
a 96-well plate coated with type I collagen (B) 
or fibronectin (C). (A) Adhesion on uncoated 
plastic surface was also analyzed. HOXA10 si-
lencing was able to increase significantly the 
adhesion of HSC-3-shHOXA10 cells to type 
I collagen and fibronectin. There was no dif-
ference in cell adhesion to plastic untreated 
surface. *P=0.049.
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reduced the invasive phenotype of breast can-
cer cells as well as modulated p53 expression 
[28]. Recently, it was reported that HOXA10 
silencing is also implicated in a lower prolifera-
tive capacity of epithelial ovarian cancer cells 
[45]. Those findings suggested that overexpres-
sion of HOXA10 promotes cell proliferation in 
OSCCs via downregulation of p21.
The results presented here also revealed that 
HOXA10 levels can modulate several biological 
processes related to metastasis, such as adhe-
sion, EMT, migration and invasion in HSC-3 
cells. Indeed, the effects of HOXA10 on some 
of those biological processes were already 
described in other cell types [36, 38, 45, 47]. 
For instance, HOXA10 is also implicated on 
controlling E-cadherin expression in endome-
trial carcinoma cells through its regulatory role 
over Snail protein [3]. HOXA10 expression has 
also been associated with cell adhesion th- 
rough regulation of ITGB3 gene, which encodes 
one of the subunits of αvβ3 integrin, in endo-
metrial [48] and myeloid cells [1]. HOXA10 has 
also been described to play a pivotal role in 
controlling the TGFβ-2 expression in myeloid 
and pancreatic cells [36, 49]. Activation of ERK 
and the TGFβ2-p38 MAPK pathway may be 
involved in these processes [36, 49]. HOXA10 
is also responsible for regulation of MMP-3 
expression in pancreatic cells [49].
HOXA10 participation on apoptosis control is 
still uncertain. On the present study, HOXA10 
knockdown was not able to influence apoptosis 
levels. Likely, apoptosis of human endometrial 
cells (HESC) [50] and acute myeloid leukemia 
cells [46] were also unaltered after HOXA10 
silencing. Nonetheless, Tang et al. [45] recently 
demonstrated that HOXA10 silencing in ovarian 
cancer cells resulted in increased apoptosis 
with concomitant enhance in caspase-3 and 
p53 expression and reduction of Bcl-2 exp- 
ression.
In essence, our data demonstrates the in vitro 
involvement of HOXA10 on oral carcinogenesis. 
The results suggest that HOXA10 modulates 
Figure 6. Effect of HOXA10 silencing on mark-
ers of epithelial-mesenchymal transition. (A) 
qPCR and (B) western blot analysis for E-cad-
herin and N-cadherin revealed that abrogation 
of HOXA10 was able to induce epithelial-mes-
enchymal transition. N-cadherin expression 
was significantly higher in HSC-3-shRNA cells, 
while E-cadherin was significantly lower.
HOXA10 expression in oral cancer
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important cellular events for the development 
and progression of OSCCs, and that its expres-
sion may be associated with a less aggressive 
tumor phenotype.
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